Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587355 | 1.00 | HTT (0.33) | HTTHPGDMMP1MMP2MMP3 | |
| SCHEMBL1559905 | 0.81 | ADRB2 (0.32) | — | |
| SCHEMBL1559904 | 0.81 | ADRB2 (0.32) | — | |
| SCHEMBL12801248 | 0.78 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL1559950 | 0.78 | ADRB2 (0.44) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL1559952 | 0.78 | ADRB2 (0.44) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL9040445 | 0.77 | LMNA (0.33) | TDP1SMN1; SMN2KDM4E | |
| SCHEMBL12801213 | 0.76 | — | — | |
| SCHEMBL3053937 | 0.76 | NR2E1 (0.33) | TSHRHIF1ACYP2D6 | |
| SCHEMBL16234248 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288587-A1 | Methods of Treating Fibrosis | ATHIRA PHARMA, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250275975-A1 | Methods of Treating Neuropathies | ATHIRA PHARMA, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250275976-A1 | Methods of Treating Neuroinflammatory Conditions | ATHIRA PHARMA, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250161308-A1 | Methods of Treating Covid-Related Disorders | ATHIRA PHARMA, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| CN-119684295-A | Bicyclic compounds for treating diseases and uses thereof | 雅斯娜制药公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-4518866-A1 | METHODS OF TREATING FIBROSIS | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4518864-A1 | METHODS OF TREATING NEUROPATHIES | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4518865-A1 | METHODS OF TREATING NEUROINFLAMMATORY CONDITIONS | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20250041307-A1 | Uses of Bicyclic Compounds for the Treatment of Diseases | ATHIRA PHARMA, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| CN-119300834-A | Methods of treating neuropathy | 雅斯娜制药公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-3099679-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | University of Connecticut (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160340346-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
| WO-2015116947-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| EP-2094646-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008075025-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| EP-0402989-B1 | Antifungal 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]triazolones and imidazolones | JANSSEN PHARMACEUTICA NV (BE) | 1996-04-03 | — | — | EP | disclosed |
| US-5075309-A | For prevention and treatment of fungal diseases in mammals | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-12-24 | — | — | US | disclosed |
| EP-0402989-A2 | Antifungal 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]triazolones and imidazolones | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | AR, ADRA1D, ADRA1B | HTT 2422/4885HPGD 3124/4885MMP1 4470/4885 |
| US-20160340346-A1 | ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF | GLI1, SHH, SMO | HTT 4242/4885HPGD 1678/4885MMP1 2149/4885 |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ADRB2, ADRB1, ADRA2A | HTT 2824/4885HPGD 2160/4885MMP1 4764/4885 |
| US-20250041307-A1 | Uses of Bicyclic Compounds for the Treatment of Diseases | HDGF, HGF, GLS2 | HTT 37/4885HPGD 438/4885MMP1 1457/4885 |
| US-20250288587-A1 | Methods of Treating Fibrosis | HDGF, HGF, MMP1 | HTT 3916/4885HPGD 604/4885MMP1 3/4885 |
| US-20250275976-A1 | Methods of Treating Neuroinflammatory Conditions | HGF, HDGF, NGF | HTT 321/4885HPGD 442/4885MMP1 106/4885 |
| US-20250275975-A1 | Methods of Treating Neuropathies | NGF, HGF, HDGF | HTT 133/4885HPGD 591/4885MMP1 344/4885 |
| US-20250161308-A1 | Methods of Treating Covid-Related Disorders | HGF, ACE2, MET | HTT 653/4885HPGD 2627/4885MMP1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.